Latest News

Roche gets FDA priority review for atezolizumab

PD-L1 (programmed death-ligand 1), which is expressed on tumour cells and tumour-infiltrating immune cells, interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, atezolizumab can trigger activation of T cells, restoring their ability to effectively detect and attack tumour cells. © Genentech


by tg

Roche is expanding its indications in cancer immunotherapy. Following FDA approvals of its PD-L1 checkpoint inhibitor atezolizumab in NSCLC and bladder cancer patients refractive to platinum-based chemotherapy, the Swiss pharma major is awaiting a FDA decision on whether the antibody is suitable as first-line treatment in a further subpopulation of bladder cancer patients.

Based on results of a single arm Phase II study, the FDA granted atezolizumab Priority Review in an additional type of advanced bladder cancer. While the agency granted accelerated market approval in May 2016 for the anti-PD-L1 antibody in patients who were treatment-refractive to platinum-based chemotherapy in neoadjuvant or adjuvant setting, the current priority review extends treatment options. Until April 2017, the agency will decide on the approval of atezolizumab in patients with bladder cancer not eligible for cisplatin chemotherapy (first-line treatment) or disease progression after 12 months of cisplatin therapy before or after surgery.

Roche’s supplemental biologics license application (sBLA) submission for atezolizumab is based on results from the Phase II IMvigor210 study. IMvigor210 is an open-label, single-arm Phase II study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic bladder cancer, regardless of PD-L1 expression. The primary endpoint of the study was objective response rate (ORR). Secondary endpoints included duration of response (DOR), overall survival (OS), progression-free survival (PFS) and safety.

ImCheck Therapeutics SAS raises €48m

The €48m financing was co-led by Pfizer Ventures, the venture capital arm of Pfizer Inc., and Bpifrance, with the new investors Wellington Partners,...

Hydrogel fights wound infection and inflammation

The new gel mimics the body’s natural defenses to tackle both inflammation and bacterial infection – two major concerns for patients recovering from...

Azeria Therapeutics bags €37.3m in Series B financing round

Series A lead investor CRT Pioneer Fund co-financed the Series B financing round. Azeria said it will use the proceeds to develop its preclinical...

Researchers identify viral inflammation switch

Their findings in mice models that were infected with the Influenza A virus may have also impact on further virally induced inflammations,researchers...

4SC expands domatinostat combo testing

In an investigator-initiated Phase Ib study (DONIMI) at NKI, 40 patients with melanoma will be enrolled  before surgery (neoadjuvant setting) to...

EU with poor success in fighting superbugs

Although some progress has been made through EU action, there is little evidence so far to suggest that the health burden of antimicrobial resistance...

GeNeuro and Karolinska Institute collaborate in multiple sclerosis

The 12-months trial, which will kick-off in QI/2020, will be led by Dr. Fredrik Piehl, head of research at the MS clinic at ASC in Stockholm, which...